Alnylam Pharmaceuticals
ALNY
#540
Rank
โ‚น3.948 T
Marketcap
โ‚น29,769
Share price
-0.40%
Change (1 day)
28.99%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น163.77

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น169.52. In 2023 the company made an earnings per share (EPS) of -โ‚น332.45 an increase over its 2022 EPS that were of -โ‚น874.91.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น163.77
2023-โ‚น332.45-62%
2022-โ‚น874.9129.03%
2021-โ‚น678.08-3.36%
2020-โ‚น701.63-8.48%
2019-โ‚น766.617.67%
2018-โ‚น711.9939.74%
2017-โ‚น509.5012.94%
2016-โ‚น451.1138.84%
2015-โ‚น324.91-32.88%
2014-โ‚น484.07259.44%
2013-โ‚น134.67-31.25%
2012-โ‚น195.89

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น678.08 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น194.49 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,061 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น258.05-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น68.75-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น22.60-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น116.78-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น32.96-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA